In Vitro Entero-Capillary Barrier Exhibits Altered Inflammatory and Exosomal Communication Pattern after Exposure to...

Area of Science:

• Gastroenterology
• Immunology
• Nanomedicine

Background:

• The intestinal microvasculature (iMV) is implicated in chronic inflammatory bowel disease (IBD) pathogenesis.
• iMV is vital for gut innate immunity and a therapeutic target for leukocyte adhesion.
• Nanoparticulate drug delivery systems are explored for targeted IBD therapy.

Purpose of the Study:

• To establish an in vitro model of iMV in IBD to study inflammation and barrier integrity.
• To evaluate the therapeutic potential of silica nanoparticles (aSNP) in an inflamed iMV model.

Main Methods:

• A co-culture model combining Caco-2 enterocytes and ISO-HAS-1 microvascular endothelial cells on a transwell system.
• Mimicking physiological and inflamed IBD conditions.
• Assessing barrier disruption via transepithelial electrical resistance (TER) and permeability (Papp).
• Measuring soluble ICAM-1, E-selectin, and IL-8 levels.
• Evaluating the effect of aSNP on inflamed endothelium and exosome/microvesicle secretion via ELISA.

Main Results:

• The developed IBD model demonstrated significant barrier disruption.
• Inflammation markers (sICAM-1, sE-selectin, IL-8) were elevated in the inflamed model.
• Exposure to aSNP reduced sICAM-1 and sE-selectin levels.
• aSNP treatment decreased the secretion of ICAM/E-selectin-bearing exosomes/microvesicles.

Conclusions:

• The in vitro model effectively replicates key aspects of iMV inflammation in IBD.
• aSNP shows potential in mitigating inflammation and altering exosomal communication in the inflamed intestinal endothelium.
• Targeting iMV with nanoparticles may offer a novel therapeutic strategy for IBD by modulating systemic communication.